Press coverage about Arcadia Biosciences (NASDAQ:RKDA) has been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arcadia Biosciences earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the basic materials company an impact score of 44.8554783721427 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Arcadia Biosciences (RKDA) traded up $0.02 during mid-day trading on Friday, reaching $0.29. 1,205,155 shares of the company’s stock were exchanged, compared to its average volume of 644,798. Arcadia Biosciences has a 12 month low of $0.18 and a 12 month high of $1.18. The firm has a market capitalization of $11.26, a PE ratio of -0.67 and a beta of -1.29.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-arcadia-biosciences-rkda-stock-price/1795744.html.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market.

Insider Buying and Selling by Quarter for Arcadia Biosciences (NASDAQ:RKDA)

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.